Ultragenyx To Present GTX-102 Angelman Syndrome Program Update At The ASF Family Conference And Research Symposium On Wednesday, July 24, 2024
Author: Benzinga Newsdesk | July 24, 2024 08:09am
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wednesday, July 24, at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.
Posted In: RARE